News

Marketing Authorization Application for Luye Pharma's Innovative Anticancer Formulation Goserelin Microspheres Accepted in China

Luye Pharma Group today announced that the marketing authorization application for Goserelin Acetate Extended-release Microspheres for Injection (LY01005), an innovative formulation for the treatment of prostate cancer, has been accepted by the Center for Drug Evaluation of China's ...
December 29,2021

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release ...

- Showing a comprehensive antidepressant efficacy and a good safety profile without an impact on sexual function - Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release ...
December 23,2021
22
2021-12
Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China’s Mainland
14
2021-12
Boan Biotech's Anti-PD-L1/TGF-β Bispecific Antibody BA1201 Approved for Clinical Trials in China
03
2021-12
Luye Pharma’s Rykindo® (Risperidone Microspheres for Injection (II)) Included in the 2021 Chinese National Reimbursement Drug List ——China’s first domestically ...
25
2021-11
Boan Biotech Publishes Results of Anti-CD25 Antibody Research in Nature Sub-Journal
24
2021-11
Boan Biotech Reaches Strategic Collaboration Agreement with Merck to Build Its “Digital Factory of the Future”
22
2021-11
Luye Pharma Holds Its First Middle East & North Africa Psychiatry Symposium——Recognition of the Group’s international academic brand set to increase with move into new region
15
2021-11
Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 Soon to Begin Clinical Trials in the U.S.
10
2021-11
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland
27
2021-10
Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 for Treating Parkinson’s Disease Soon to Begin Clinical Trials in China
13
2021-10
Marketing Authorization Application for Boan Biotech's Denosumab Injection Accepted in China
1
2
3
4
5
News
Marketing Authorization Application for Luye Pharma's Innovative Anticancer Formulation ...
Luye Pharma Group today announced that the marketing authorization application for Goserelin Acetate Extended-release Microspheres for Injection (LY01005), an innovative formulation for the treatment of prostate cancer, has been ...

December 29,2021
Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant ...
- Showing a comprehensive antidepressant efficacy and a good safety profile without an impact on sexual function - Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new ...

December 23,2021
12-22
2021
Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China’s Mainland
12-14
2021
Boan Biotech's Anti-PD-L1/TGF-β Bispecific Antibody BA1201 Approved for Clinical Trials in China
12-03
2021
Luye Pharma’s Rykindo® (Risperidone Microspheres for Injection (II)) Included in the 2021 Chinese National Reimbursement Drug List ——China’s first domestically created innovative injection of microspheres will benefit more patients
11-25
2021
Boan Biotech Publishes Results of Anti-CD25 Antibody Research in Nature Sub-Journal
11-24
2021
Boan Biotech Reaches Strategic Collaboration Agreement with Merck to Build Its “Digital Factory of the Future”
11-22
2021
Luye Pharma Holds Its First Middle East & North Africa Psychiatry Symposium——Recognition of the Group’s international academic brand set to increase with move into new region
11-15
2021
Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 Soon to Begin Clinical Trials in the U.S.
11-10
2021
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland
10-27
2021
Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 for Treating Parkinson’s Disease Soon to Begin Clinical Trials in China
10-13
2021
Marketing Authorization Application for Boan Biotech's Denosumab Injection Accepted in China
1
2
3
4
5